Ryan Deschner
Stock Analyst at Raymond James
(4.55)
# 1,019
Out of 5,090 analysts
73
Total ratings
50%
Success rate
25.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | n/a | $151.58 | - | 3 | Oct 16, 2026 | |
| LQDA Liquidia | Reiterated: Buy | $106 → $53 | $44.99 | +17.80% | 14 | Oct 1, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | n/a | $30.53 | - | 8 | Sep 15, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $27 → $40 | $13.81 | +189.65% | 6 | Aug 7, 2026 | |
| ACOG Alpha Cognition | Initiated Coverage: Buy | $20 | $9.19 | +117.63% | 1 | Jul 10, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $10 | $0.863 | +1,058.75% | 5 | Jul 8, 2026 | |
| ACHV Achieve Life Sciences | Initiated Coverage: Buy | $20 | $7.19 | +178.16% | 1 | Jun 26, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $14 → $10 | $1.44 | +594.44% | 2 | Jun 26, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | n/a | $26.86 | - | 2 | Jun 24, 2026 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | n/a | $82.70 | - | 5 | Jun 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $21 | $11.75 | +78.72% | 1 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.72 | +424.78% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $110 → $165 | $86.39 | +90.99% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $23 | $14.20 | +61.97% | 2 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.66 | - | 11 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $12 | $3.10 | n/a | 4 | Aug 5, 2025 |
Palvella Therapeutics
Oct 16, 2026
Reiterated: Buy
Price Target: n/a
Current: $151.58
Upside: -
Liquidia
Oct 1, 2026
Reiterated: Buy
Price Target: $106 → $53
Current: $44.99
Upside: +17.80%
Vera Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $30.53
Upside: -
Trevi Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $27 → $40
Current: $13.81
Upside: +189.65%
Alpha Cognition
Jul 10, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $9.19
Upside: +117.63%
Tvardi Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $10
Current: $0.863
Upside: +1,058.75%
Achieve Life Sciences
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.19
Upside: +178.16%
ProQR Therapeutics
Jun 26, 2026
Reiterated: Buy
Price Target: $14 → $10
Current: $1.44
Upside: +594.44%
Viking Therapeutics
Jun 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $26.86
Upside: -
Dianthus Therapeutics
Jun 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $82.70
Upside: -
Jun 10, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $11.75
Upside: +78.72%
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $1.72
Upside: +424.78%
May 7, 2026
Reiterated: Buy
Price Target: $110 → $165
Current: $86.39
Upside: +90.99%
Mar 13, 2026
Upgraded: Buy
Price Target: $23
Current: $14.20
Upside: +61.97%
Jan 9, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.66
Upside: -
Aug 5, 2025
Reiterated: Buy
Price Target: $11 → $12
Current: $3.10
Upside: n/a